Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869686 | 0.90 | CA1 (0.52) | CA1CA2CA9HTR7ADRA1D | |
| SCHEMBL14869660 | 0.86 | CA1 (0.49) | CA1CA2CA9HTR7ADRA1D | |
| SCHEMBL1938196 | 0.80 | HTR7 (0.56) | CA1CA2CA9HTR7ADORA3 | |
| SCHEMBL14869694 | 0.78 | CA1 (0.51) | CA1CA2CA9APPCNR2 | |
| SCHEMBL14869622 | 0.76 | CA1 (0.49) | CA1CA2CA9ADORA2AAPP | |
| SCHEMBL14869377 | 0.75 | ADORA2A (0.51) | CA1CA2CA9ADORA3ADORA2A | |
| Bicarbonate SCHEMBL1939053 | 0.75 | HDAC1 (0.54) | CA1CA2CA9HTR7ADORA3 | |
| SCHEMBL14869691 | 0.74 | CA1 (0.54) | CA1CA2CA9HTR7CNR2 | |
| SCHEMBL14869316 | 0.74 | ALPL (0.50) | CA1CA2CA9HTR7ADRA1D | |
| SCHEMBL15100685 | 0.74 | CA1 (0.38) | CA1CA2CA9HTR7ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941245-B1 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | ANJI PHARMACEUTICALS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2023-09-14 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| EP-2800561-B1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMA US LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| WO-2014107617-A1 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | ELCELYX THERAPEUTICS, INC. (US) | 2014-07-10 | — | — | WO | disclosed |
| US-20140193498-A1 | Compositions and Methods for Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-07-10 | — | — | US | disclosed |
| US-20140193498-A1 | Compositions and Methods for Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-07-10 | — | — | US | disclosed |
| WO-2014011926-A1 | COMPOSITIONS COMPRISING STATINS, BIGUANIDES AND FURTHER AGENTS FOR REDUCING CARDIOMETABOLIC RISK | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013103919-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | CA1 3461/4885CA2 1106/4885CA9 640/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | CA1 3461/4885CA2 1106/4885CA9 640/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | CA1 3461/4885CA2 1106/4885CA9 640/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | CA1 3461/4885CA2 1106/4885CA9 640/4885 |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | FABP2, GPR119, PNLIP | CA1 4452/4885CA2 2254/4885CA9 1691/4885 |
| US-20140193498-A1 | Compositions and Methods for Treating Metabolic Disorders | SLC5A2, SLC10A1, GPR119 | CA1 4492/4885CA2 1680/4885CA9 871/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | CA1 3461/4885CA2 1106/4885CA9 640/4885 |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | FABP2, GPR119, PNLIP | CA1 4463/4885CA2 2345/4885CA9 1540/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | CA1 3320/4885CA2 1136/4885CA9 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.